This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ThromboGenics NV - Business Update

LEUVEN, Belgium, May 10, 2012 /PRNewswire/ --

Regulated Information

Disclosure in accordance with the law of May 2, 2007

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today issued a business update and its first-quarter financial results for the period ending 31 March 2012.

Highlights (including post-quarter events)

Ocriplasmin

  • ThromboGenics signed an important strategic deal with Alcon, the global leader in eye care, to commercialize ocriplasmin outside the U.S. ThromboGenics will receive up to €375 million in upfront and milestone payments plus royalties commensurate with a product that has successfully completed Phase III development and that has been filed for regulatory approval
  • The Company resubmitted a BLA for ocriplasmin, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole, with the FDA in order to meet the agency's Priority Review timelines. The ocriplasmin Marketing Authorization Application (MAA) was filed with the EMA in Europe in October 2011

Financial Highlights

  • ThromboGenics raised €77.8 million through a private placement with a range of domestic and international investors at a price of €24 per share
  • The Company had €127 million in cash and cash investments as of 31 March 2012 compared with €101.1 million at the end of March 2011. The Q1 2012 figure excludes the proceeds from the private placement which were received in early April
  • Reported revenues of €75 million in the first three months of 2012 versus no revenue in the first three months of 2011

Patrik De Haes, CEO of ThromboGenics, said:  

"ThromboGenics has made a positive start to 2012. Our strategic agreement with Alcon, the world leader in eyecare, provides us with the ideal partner to commercialize ocriplasmin outside the U.S. We will also benefit from Alcon's significant clinical development expertise as we jointly fund the evaluation of ocriplasmin for additional ophthalmic indications.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,071.22 -41.93 -0.24%
S&P 500 1,977.80 -5.05 -0.25%
NASDAQ 4,505.8520 -6.3420 -0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs